CEPI vergibt einen Vertrag über 34 Millionen US-Dollar an CureVac zur weiteren Entwicklung des The RNA Printer™ – eine disruptive transportable Plattform zur Herstellung von mRNA-Impfstoffen für die schnelle Bekämpfung zahlreicher Krankheiten
27 févr. 2019 07h00 HE
|
CureVac AG
Oslo, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Die Koalition für Innovationen zur Vorsorge vor Epidemien (Coalition for Epidemic Preparedness Innovations, CEPI) und die CureVac AG, ein biopharmazeutisches...
CureVac to Present at the 8th Annual Leerink Partners Global Healthcare Conference
19 févr. 2019 07h00 HE
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Feb. 19, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Dan...
CureVac ernennt Dr. Stefan Müller zum Vice President Preclinical
04 févr. 2019 07h00 HE
|
CureVac AG
TÜBINGEN, Deutschland and BOSTON, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Das biopharmazeutische Unternehmen CureVac AG, Pionier im Bereich mRNA-basierter Impfstoffe und Therapeutika, gibt heute die...
CureVac Appoints Stefan Mueller, Ph.D., as Vice President Preclinical
04 févr. 2019 07h00 HE
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Feb. 04, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today the...
CureVac ernennt Dr. med. Dimitris Voliotis, MD, zum Chief Development Officer
28 janv. 2019 07h00 HE
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Das biopharmazeutische Unternehmen CureVac AG, Pionier im Bereich mRNA-basierter Impfstoffe und Therapeutika, gibt heute die...
CureVac Appoints Dimitris Voliotis, M.D., Dr. med., as Chief Development Officer
28 janv. 2019 07h00 HE
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Jan. 28, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today the...
CureVac erhält US-Patent für mRNA-basierte RSV-Impfung von Säuglingen
08 janv. 2019 07h00 HE
|
CureVac AG
TÜBINGEN, Deutschland and BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Das biopharmazeutische Unternehmen CureVac AG, Pionier im Bereich mRNA-basierter Impfstoffe und Therapeutika, gibt bekannt,...
CureVac Announces U.S. Patent Grant for mRNA Vaccination of Infants Against RSV
08 janv. 2019 07h00 HE
|
CureVac AG
Important New Patent to Allow CureVac to Develop Vaccine Candidate for Neglected Respiratory Condition TÜBINGEN, Germany and BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully...
CureVac to Present at the 19th Annual Piper Jaffray Healthcare Conference
21 nov. 2018 07h00 HE
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Nov. 21, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Dan...
University of Tübingen Names CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, Honorary Senator
07 nov. 2018 16h30 HE
|
CureVac AG
TÜBINGEN, Germany and BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, congratulates CureVac...